Efgartigimod (Vyvgart) (AChR-positive gMG)

Company: Argenx

Clinical trial(s): ADAPT (Stage 3 complete) More information and a paediatric study (actively recruiting) in Oxford.

NICE status: Negative Final Guidance published in June 2025 after an appeal from Argenx and myaware.

MHRA status: Approved

Learn more about Efgartigimod.